Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

BACKGROUND: Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence suggests that combinations of these two classes of ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorusso, Domenica, Maltese, Giuseppa, Sabatucci, Ilaria, Cresta, Sara, Matteo, Cristina, Ceruti, Tommaso, D’Incalci, Maurizio, Zucchetti, Massimo, Raspagliesi, Francesco, Sonetto, Cristina, Sinno, Valentina, Ronzulli, Dominique, Giolitto, Serena, de Braud, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810645/
https://www.ncbi.nlm.nih.gov/pubmed/33369704
http://dx.doi.org/10.1007/s11523-020-00780-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810645/
https://www.ncbi.nlm.nih.gov/pubmed/33369704
http://dx.doi.org/10.1007/s11523-020-00780-4

Ejemplares similares